Edaravone Sublingual Tablet(Nanjing Baixinyu Pharma)

依达拉奉舌下片（南京百鑫愉医药）

Report date: 2026/02/25 20:02:36

Base Information

Drug NameEdaravone Sublingual Tablet(Nanjing Baixinyu Pharma)
Drug Alias NameEdaravona依迭拉奉Norphenazone依达拉奉舌下片（2.2类改良型）Edaravonum +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFree radicals scavengersantioxidant
TargetsFree radicals
Therapy Area/IndicationsAmyotrophic Lateral SclerosisStrokeBrain Infarction
Global Approved IndicationsAmyotrophic Lateral Sclerosis
Approved Indications in ChinaAmyotrophic Lateral Sclerosis
Original Approved Country/TerritoryMainland China
Original Approved Date2022/09/14
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNanjing Baixinyu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Tiantan Hospital, Capital Medical UniversityNanjing Baixinyu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisStrokeBrain Infarction
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG